The FDA last week approved Roche’s Vabysmo in neovascular (or “wet” age-related) macular degeneration and diabetic macular edema, eye disorders that are among the leading causes of blindness. The drug, which is the first FDA-approved bispecific antibody for the eye, will have to face off against Regeneron’s blockbuster Eylea. For the treatment of neovascular macular degeneration, Eylea holds covered or better status for 57% of all insured lives under the pharmacy benefit. Eylea is not covered for 30% of lives.
SOURCE: MMIT Analytics, as of 2/2/22